Revenue, 2025

USD 3.09 Billion

Forecast, 2035

USD 8.06 Billion

CAGR, 2026-2035

10.07%

Report Coverage

Global

Brain Cancer Market Trends for 2026

The global brain cancer market size was estimated at USD 3.09 billion in 2025 and is predicted to increase from USD 3.4 billion in 2026 to approximately USD 8.06 billion by 2035, expanding at a CAGR of 10.07% from 2026 to 2035.

The brain cancer market is growing due to a growing population with stressful life conditions, a wrong diet, and a busy lifestyle.

Key Takeaways

• Brain cancer sector pushed the market to USD 3.4 billion by 2026.
• Long-term projections show USD 8.06 billion valuation by 2035.
• Growth is expected at a steady CAGR of 10.07% in between 2026 to 2035.
• North America dominated the brain cancer market by 40% share in 2025.
• Asia Pacific is expected to grow at the fastest CAGR in the market during the forecast period.
• By product/solution type, the therapeutic treatments segment dominated the market by 55% share in 2025.
• By product/solution type, the diagnostic imaging segment is expected to grow at the fastest CAGR in the market during the forecast period.
• By treatment modality, the chemotherapy segment led the market with share of 30% in 2025.
• By treatment modality, the immunotherapy segment is expected to grow at the fastest CAGR in the market during the forecast period.
• By diagnosis & monitoring technology, the MRI & CT imaging segment led the brain cancer market by 45% share in 2025.
• By diagnosis & monitoring technology, the PET imaging segment is expected to grow at the fastest CAGR in the market during the forecast period.
• By end user, the hospitals segment led the market by 50% share in 2025.
• By end user, the specialty cancer centers segment is expected to grow at the fastest CAGR in the market during the forecast period.

Market Overview: What is Brain Cancer?

The brain cancer market involves a multidisciplinary strategy, significantly using surgery, radiation therapy, and chemotherapy, often integrated with novel strategies such as targeted therapy, immunotherapy, and tumor treating fields (TTFields).  People who have been exposed to a strong type of radiation called ionizing radiation have an increased risk of brain tumors. Patients with an increased risk of brain tumors may consider screening tests. Brain tumors occur in nerves, the pituitary gland, and the pineal gland.

Brain and Other Nervous System Cancer in 2025

How is AI Governing the Brain Cancer Market?

The integration of AI-driven technology into brain cancer drives the growth of the market, as AI-driven technology brought transformative innovations to brain tumor management, using imaging, histopathological, and genomic devices for effective identification, categorization, outcome prediction, and treatment planning. AI-driven models efficiently impact various stages of the diagnostic and therapeutic process.

Future Outlook & Trends in the Brain Cancer Market

Personalized Cancer Vaccines:

Personalized cancer vaccines have high specificity and work by provoking an immune response directly against cancer cells, thereby reducing the destruction of healthy tissue and lowering off-target effects.

Antibody-Drug Conjugates:

Antibody drug conjugated nanoparticles allow the selective targeting of brain tumor cells by exploiting surface receptors that are overexpressed both on tumor cells and on the endothelial cells of the blood–brain barrier (BBB),  transferrin receptor (TfR), and epidermal growth factor receptor (EGFR).

Targeted IDH Inhibitors:

Effectiveness of IDH inhibitors in managing tumors with IDH mutations is superior to that of conventional healthcare therapy, potentially offering more healthcare benefits to patients.

Key Indicators and Highlights

Segmentation Analysis

Product/Solution Type Insights

Which Product/Solution Type Led the Brain Cancer Market in 2025?

In 2025, the therapeutic treatments segment held the dominant market share of 55%, as these therapies supports treat brain cancer in children. It supports managing cancers that are close to significant parts of the brain. This treatment shrinks the tumor or slows down its growth, which helps people live longer and helps with symptoms. Immunotherapy provides promising choices for managing brain cancer, which is traditionally treated with chemotherapy, radiation therapy, and surgery.

Diagnostic Imaging

Whereas the diagnostic imaging segment is the fastest-growing in the market, as these well-developed imaging processes have shown some promise in differentiating PsP from true tumor reappearance in recurrent cancer. Its capability to produce detailed images of the brain, differentiate cancer types, and guide treatment makes it a significant tool in modern oncology and neurology.

Treatment Modality Insights

Why did the Chemotherapy Segment Dominate the Market in 2025?

The chemotherapy segment is dominant in the brain cancer market by 30% share in 2025, as chemotherapy is highly efficient in supervising the growth and spread of brain cancer. It works by inhibiting the division of quickly multiplying tumor cells, therefore lowering cancer size and preventing further progression. Oncologists employ many chemotherapy medicines to target brain tumours. Based on the type of cancer, location, and grade, these medicine be used alone or in combination form.

Immunotherapy

Whereas the immunotherapy segment is the fastest growing in the market, as it is novel and advancing brain cancer immunotherapies have the strength to lower the challenging effects and enhance survival rates for patients with brain cancer. Immunotherapy strengthens or reprograms the body's natural immune response to target and eradicate tumor cells.  Immunotherapy has evolved as a promising approches for tackle the brain metastases.

Diagnosis & Monitoring Technology Insights

Why did the MRI & CT Imaging Segment Dominate the Market in 2025?

The MRI & CT Imaging segment is dominant in the brain cancer market by 45% share in 2025, as this type of imaging plays a significant role in the management of patients with brain cancer. The technical advancement of computed tomography (CT) and magnetic resonance (MRI), with the development of novel imaging processes, strongly enhanced the identification and characterization of brain cancer.

PET Imaging

Whereas the PET imaging segment is the fastest growing in the market, as this is a functional imaging technology that plays an increasingly significant role in the management of brain cancer. Positron emission tomography (PET) scans identify early symptoms of cancer, heart disease, and brain conditions. It includes an injection of a safe radioactive tracer that helps detect diseased cells.

End User Insights

Why did the Hospitals Segment Dominate the Market in 2025?

The hospitals segment is dominant in the brain cancer market by 50% share in 2025, as some kinds of brain cancer, like meningioma, ependymoma, and oligodendroglioma, are extremely treatable. In a hospital treating brain cancer, choices include palliative surgery to lower mass effect, high-dose radiation treatment, chemotherapy, and evolving immunotherapy.

Specialty Cancer Centers

Whereas the specialty cancer centers segment is the fastest growing in the market, as specialty cancer centers manage brain cancer with targeted, multidisciplinary strategies, significantly using surgery such as craniotomy, minimally invasive to get rid of tumors, followed by advanced radiation therapy like Gamma Knife, and Proton Therapy for remaining cells, and then chemotherapy.

Regional Insights

How did North America Dominate the Market in 2025?

In 2025, North America led the brain cancer market by 40% share, as advancements in scanning and diagnostic technology and changes in environmental challenging factors, the incidence of brain and CNS cancers is expected to grow. Adults aged more than 65 are a fast-growing segment of America's population, who are more prone to brain cancer. Recent research indicates that there is a potential link between moderate to severe traumatic brain injury and a future risk of brain cancer.

U.S. Market Trends

Brain cancer makes up around 1% of the every year cancer diagnoses in the US, affecting the psychological, physical, and cognitive health of the U.S. population.  In 2025, 2,041,910 novel cancer cases and 618,120 cancer deaths are estimated to occur in the United States.

Asia Pacific: Growing Chronic Illness with Brain Tumor

Asia Pacific is set to experience rapid growth in the brain cancer market by 22% share, as significant increase in brain tumor incidence rates both in males and females in this area. Chronic illness integrated with functional damage often results in an increased requirement for health care and supportive long-term care (LTC) solutions.  An aging population with the rising challenges of patients with chronic conditions in Asia needs effective health systems with integrated care.

India Market Trends

In India, every fourth person over 60 years and every fifth Indian over 45 years is diagnosed with poor health. India's cancer challenges are growing more rapidly than the worldwide average. Due to the poor healthcare technology in rural regions, lifestyle and environmental factors, and late identification, which drives the growth of the market is expected to grow.

Europe: Increasing Spending on Brain Cancer

Europe is experiencing substantial growth in the brain cancer market with share of 25%, as brain and CNS cancers are the most common solid cancers in children and adolescents, posing a significant challenge to life quality and expectancy. Cancer care investing has increased in Europe over the past period, significantly because of the increasing number of cancer patients and spending in novel technology, which drives the growth of the market.

UK Market Trends

In the UK, brain cancer, like most other cancers, becomes more common as people age. Each year in the UK, about 13,000 people are diagnosed with a brain cancer. There are around 5,500 deaths because of brain cancer each year in the UK, more than 100 deaths each week. Developments in low-dose CT, MRI, and molecular imaging have recently made it possible to identify cancer earlier, with greater accuracy and lower challenges.

How is the Market Growing in the South American Region?

South America is experiencing growth in the market, driven by improved access to diagnostic imaging such as MRI, more clinical trials, and increased investment in oncology infrastructure, particularly in Brazil. The rise in cases, especially meningiomas, and an aging population are heightening the demand for treatment options. Enhanced availability of MRI and advanced neuroimaging in urban areas has led to better detection rates of brain and CNS tumors. Significant funding for cancer treatment facilities and heightened awareness of the importance of early diagnosis are also fueling this growth. The expansion of clinical trials by international pharmaceutical companies is introducing innovative therapies to the region, invigorating the market.

Brazil Market Trends

Brazil is emerging as a key player in the Latin American brain cancer treatment and research market due to high disease rates, advanced medical facilities, and active clinical trials. The brain tumor treatment market in Brazil is projected to grow significantly, supported by an aging population and increased oncology investment. With new cancer cases reported annually by the National Cancer Institute (INCA) and a large elderly demographic, Brazil provides a diverse patient base for research. The country is also a neurosurgery hub in the region, boasting specialized cancer research centers and oncology clinics in cities like São Paulo, Rio de Janeiro, and Porto Alegre, capable of conducting complex multinational studies. Investment in advanced technologies, such as CAR-T cell therapy and new drug delivery systems for the blood-brain barrier, has strengthened Brazil's position in cutting-edge cancer treatments.

How is the Market Growing in the MEA Region?

The brain cancer market in the Middle East and Africa (MEA) is expanding by 6% share due to rising cancer cases, advancements in diagnostic tools like MRI and CT scans, and improvements in healthcare systems. Government initiatives for early detection, increased awareness, and a growing number of skilled oncologists are also driving this growth. Advanced imaging technologies and molecular diagnostics are enabling earlier and more accurate detection of brain tumors. Government programs and collaborations with international firms are enhancing cancer treatment facilities and access to local treatments. The market is increasingly shaped by specialized methods like personalized medicine and immunotherapies, supported by a rise in clinical trials in the region.

UAE Market Trends

The UAE has emerged as a key player in the market, encompassing diagnostics and treatments. This growth is driven by significant government investments in healthcare, advanced technologies, and its status as a medical tourism hub. The market is rapidly expanding, with the UAE and Saudi Arabia leading the Gulf Cooperation Council (GCC) region due to high health spending and strong public-private partnerships. The region is adopting AI-driven imaging analytics like PET/MRI, robotic surgical systems, and nanotechnology for drug delivery. The UAE is enhancing its healthcare by partnering with global tech and pharmaceutical companies such as GE Healthcare, Roche, and Siemens to provide high-quality diagnostics and treatments. The government is focused on healthcare, creating a regulatory environment that encourages pharmaceutical innovation and accelerates drug approvals, often aligning with FDA timelines.

Value Chain Analysis – Brain Cancer Market

R&D:

• Research and development (R&D) processes in brain cancer treatment includes a inclusive, many-stage pipeline, from drug development and preclinical testing to clinical trials and regulatory processes.
• Key Players: Apollo Hospitals and HCG Hospitals

Management Processes:

• The management of brain cancer includes a complete, multidisciplinary approach that generally includes diagnosis and staging, significant cancer treatments, and ongoing supportive and rehabilitative care.
• Key Players: Max Healthcare and Fortis Hospitals

Patient Services:

• Patient services for brain cancer mix high-precision healthcare treatments with inclusive supportive care to address physical, emotional, and practical risks via the treatment processes.
• Key Players: Merck and Medanta

Latest Updates of Key Players in the Brain Cancer Market

SWOT Analysis

Strengths

• Robotic surgery in brain tumor management is its ability to reduce trauma to adjacent healthy brain tissue.
• Immunotherapy offers promising options for treating brain cancer, which is traditionally treated with chemotherapy, radiation therapy, and surgery.

Weaknesses

• Adverse effects of brain cancer are severe, though, leading to pain, modifications in normal body functions, deterioration of quality of life, permanent injury, and death.
• Based on the region of the brain operated on, patients experience temporary or permanent challenges with speech, weakness in limbs, lower balance, or seizures.

Opportunities

• Recent developments involve non-invasive diagnostic technology that predicts glioma proliferation, differentiates gliomas from benign cancer, and offers molecular profiles that additional refine diagnostics.
• Explore the advanced brain cancer treatment breakthroughs, involving personalized therapies, immunotherapies, and targeted strategies for enhanced results.

Threats

• Fatigue is the most common adverse-effect of brain cancer and its treatment.
• Radiotherapy to the brain cancer often led the hair loss in the managed area, which is temporary or permanent based on the dose.

Recent Developments in the Brain Cancer Market

• In December 2025, Curasight A/S announced the successful and safe dosing of the first patient in the Phase 1 trial using uTREAT in brain cancer.
• In October 2025, Northwest Biotherapeutics, Inc., a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, announced that its acquisition of Advent BioServices Ltd. had closed.

Segments Covered in the Report

By Product/Solution Type

• Therapeutic Treatments
• Diagnostic Imaging
• Surgical Devices
• Supportive Care Products

By Treatment Modality

• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Radiation Therapy
• Surgery (Neurosurgical)
• Tumor Treating Fields (TTF)

By Diagnosis & Monitoring Technology

• MRI & CT Imaging
• PET Imaging
• Molecular & Genetic Testing
• AI-Based Imaging Analysis
• Liquid Biopsy

By End User

• Hospitals
• Specialty Cancer Centers
• Diagnostic Laboratories
• Academic & Research Institute

By Region

• North America
  • U.S.
  • Canada 
  • Mexico 
  • Rest of North America
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Europe 
  • Western Europe 
    • Germany 
    • Italy
    • France
    • Netherlands
    • Spain
    • Portugal 
    • Belgium
    • Ireland
    • UK 
    • Iceland 
    • Switzerland
    • Poland
    • Rest of Western Europe
  • Eastern Europe 
    • Austria
    • Russia & Belarus 
    • Türkiye
    • Albania 
    • Rest of Eastern Europe 
• Asia Pacific
  • China 
  • Taiwan
  • India 
  • Japan 
  • Australia and New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea 
  • Rest of APAC 
• MEA 
  • GCC Countries
    • Saudi Arabia 
    • United Arab Emirates (UAE)
    • Qatar 
    • Kuwait 
    • Oman 
    • Bahrain 
  • South Africa
  • Egypt 
  • Rest of MEA